苏州天马精细化学品股份有限公司 证券代码：002453 证券简称：天马精化 苏州天马精细化学品股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|-------------------------------------------| | | ■ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 兴业证券：洪依真 招商证券：于庭泽、刘泽晶 | | | | 国泰君安：李沐华 方正证券：翟炜 | | | | 北京鸿道：熊胜江 九州证券：岳志强 | | 参与单位名称及 | | 泰达宏利：孟杰 长盛基金：代毅、黄聪 | | 人员姓名 | | 正心投资：孙书滨 国投安信：王嘉宁 | | | | 中视领成：李飞 信达证券：招斯喆、袁海宇 | | | 永源安泰：汪洋 | | | 时间 | 2017 年 9 月 25 | 日 14 ...

苏州天马精细化学品股份有限公司 证券代码：002453 证券简称：天马精化 苏州天马精细化学品股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |------------------------------|-------------------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：002453 证券简称：华软科技 金陵华软科技股份有限公司 投资者关系活动记录表 编号：20211121 | --- | --- | --- | --- | --- | |----------------------|----------------------------------------|-----------------------|------------------|----------------------------------------| | | | | | | | 投资者关系活动类别 | □特定对象调研 | □分析师会议 | | | | | □媒体采访 | □业绩说明会 | | | | | □新闻发布会 | □路演活动 | | | | | □现场参观 ■ | 其他（电话会议） | | | | | 国盛证券 | | | 王席鑫、杨义韬、孙琦祥、丁妍乔、尹乐川 | | | 长江养老 马睿 | 上投摩根基金 赵隆隆 | | 冯自力、陈雁冰、 | | | 华宝基金 杨奇 | 国寿养老 刘统 | | | | | 国寿安保基金 | | | 李博闻、宋义潞、祁善斌、撒伟旭、杨子贤 | ...

Group 1: Financial Performance - The main reason for the company's loss in Q1 was the expense amortization of the equity incentive plan amounting to 17.45 million yuan [2] - The company's ordinary shareholders totaled 23,223 as of March 31, 2022 [5] - The revenue growth rate for the fluorescent whitening agent business reached 305.14% last year [5] Group 2: Business Operations - The chemical segment showed significant revenue growth, while the supply chain management segment's revenue growth was relatively small [3] - The production line for cardon anhydride at the subsidiary Aodai Chemical is still under construction, with expected revenue impact upon completion [2] - The company plans to enhance its market development and optimize its marketing strategies in 2022 [3] Group 3: Strategic Developments - The company is open to introducing new strategic investors [6] - The divestment of the supply chain management business is ongoing, with completion expected this year [7] - The company aims to focus on fine chemicals and expand into new materials, particularly in the renewable energy sector [8] Group 4: Research and Development - The company has approximately 150 R&D personnel and plans to increase investment in new pharmaceutical and pesticide intermediates [5] - The company is actively developing new products related to COVID-19 treatment and enhancing its production capabilities [5] - The company emphasizes quality management and aims to maintain a competitive edge through strict quality control [6]

金陵华软科技股份有限公司 2022 年第三季度报告 证券代码：002453 证券简称：华软科技 公告编号：2022-102 金陵华软科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员) 声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 金陵华软科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|------ ...

Financial Performance - The company's operating revenue for the reporting period was ¥1,849,336,942.65, representing a 12.01% increase compared to ¥1,651,045,834.95 in the same period last year [22]. - Net profit attributable to shareholders was ¥26,190,781.03, reflecting a 33.31% increase from ¥19,646,212.71 year-on-year [22]. - The net cash flow from operating activities was -¥123,714,182.33, a significant decrease of 445.03% compared to ¥35,856,444.32 in the previous year [22]. - The total assets at the end of the reporting period amounted to ¥3,616,944,532.98, which is a 5.56% increase from ¥3,426,327,314.10 at the end of the previous year [22]. - The company's revenue for the reporting period reached ¥1,849,336,942.65, representing a year-on-year increase of 12.01% due to the growth in supply chain management business [40]. - Operating costs increased to ¥1,681,772,858.54, reflecting a year-on-year growth of 10.22% aligned with the expansion of supply chain management services [40]. - The company's net profit after deducting non-recurring items was ¥37,464,000, excluding the impact of employee stock option expenses of ¥34,775,400 [41]. - Domestic revenue was ¥1,718,821,446.46, making up 92.94% of total revenue, while international revenue increased by 80.76% to ¥130,515,496.19 [41]. - The gross profit margin for the supply chain management business was 4.31%, a decrease of 0.64% compared to the previous year [42]. - The gross profit margin for the fine chemicals business improved to 24.16%, an increase of 5.16% year-on-year [42]. - The company reported investment income of ¥2,241,777.73, contributing 5.32% to total profit, primarily from financial product returns [44]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts [4]. - The report includes a section on potential risks and corresponding countermeasures faced by the company [4]. - The company faced macroeconomic risks that could impact product exports and future performance, prompting an increase in R&D for new products and technologies [71]. - The company plans to optimize procurement strategies to mitigate risks from raw material price fluctuations and enhance production efficiency [72]. - The company aims to increase R&D investment to improve product quality and reduce costs in response to intensified market competition [72]. Corporate Governance and Compliance - The management team has confirmed the accuracy and completeness of the financial report for the first half of 2022 [4]. - The company is committed to ensuring the authenticity of its financial statements, as stated by its responsible personnel [4]. - The report outlines the company's governance structure and social responsibility initiatives [5]. - The company has not faced any significant litigation or administrative penalties in the last three years, maintaining a strong compliance record [106]. - The company has maintained a clean record regarding insider trading, with no investigations or penalties in the last three years [106]. Investment and Capital Management - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves [5]. - The company has ongoing significant non-equity investments, including a project for an annual production of 12,000 tons of lithium battery electrolyte additive, with an actual investment of ¥12,026,300.00 [53]. - The total investment amount for the reporting period was ¥17,320,427.49, representing a 13.21% increase compared to ¥15,300,000.00 in the same period last year [51]. - The company reported a commitment to provide accurate and complete information regarding the asset restructuring, ensuring no misleading statements or omissions [109]. - The company has committed to legal responsibility in case of any violations of the stated commitments and declarations [106]. Environmental and Social Responsibility - The company has established a comprehensive safety management system to minimize safety and environmental risks during production [73]. - The company has implemented a VOCs online monitoring system to ensure compliance with environmental regulations [89]. - The company has established a hazardous waste storage facility with a capacity of 500 tons, ensuring zero emissions through qualified third-party disposal [88]. - The company has committed to reducing carbon emissions through various measures, although specific results were not detailed in the report [100]. - The company has provided comprehensive social insurance for employees, including pension and mutual aid mechanisms for those in need [100]. Shareholder Information - The company is listed on the Shenzhen Stock Exchange with the stock code 002453 [16]. - The total number of ordinary shareholders at the end of the reporting period is 22,932 [174]. - The largest shareholder, Wufu Technology Group, holds 32.94% of shares, totaling 311,036,703 shares [174]. - The company has not reported any changes in shareholding structure or significant financial impacts from share changes [173]. - The company has not engaged in any share buyback or repurchase activities during the reporting period [173]. Research and Development - Research and development investment decreased by 27.13% to ¥12,085,501.83, attributed to delays caused by factory maintenance [40]. - The company has over 100 patents, reflecting its commitment to technology innovation and research [36]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth [196].

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 20% in the electronic chemicals segment[14]. - The company’s operating revenue for 2021 was ¥3,942,318,263.57, representing a 43.91% increase compared to ¥2,739,390,050.46 in 2020[22]. - The total revenue for 2021 reached ¥3,942,318,263.57, representing a year-on-year increase of 43.91% compared to ¥2,739,390,050.46 in 2020[57]. - The company reported a significant amount of idle raised funds used for cash management, with details provided in the special report[99]. - The company achieved a net profit of RMB 6,200 million for the year 2020, with adjusted commitments for 2021 set at RMB 10,675 million and for 2022 at RMB 12,875 million[199]. Strategic Direction and Market Expansion - The company has a focus on expanding its market presence and developing new products and technologies[5]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[20]. - The company is actively exploring partnerships with international firms to enhance its technological capabilities and market reach[21]. - The company is pursuing market expansion, targeting Southeast Asia as a new growth area, with plans to establish a local office by Q3 2022[135]. - The company plans to continue expanding its market presence and product offerings in the future[87]. Research and Development - Investment in R&D for new products reached RMB 50 million, focusing on advanced chemical materials and pharmaceuticals[21]. - The R&D budget has been increased by 30% to 150 million RMB for 2022, focusing on artificial intelligence and machine learning technologies[135]. - R&D investment amounted to ¥37,023,258.49, a 123.84% increase from the previous year, representing 0.94% of operating income[75]. - The company plans to increase its R&D investment in new products, focusing on two major directions to enhance competitiveness[115]. - The company has established a joint R&D center with Beijing University of Chemical Technology to enhance its technological strength[48]. Corporate Governance and Compliance - Financial reports are guaranteed to be true, accurate, and complete by the company's responsible personnel[4]. - The company is committed to maintaining transparency in its financial disclosures and corporate governance practices[4]. - The company strictly adhered to information disclosure regulations, ensuring timely and accurate communication with investors through designated media[126]. - The company has a robust internal information confidentiality system in place, complying with regulations regarding insider information management[126]. - The company has established an independent personnel management system, ensuring no interference from the controlling shareholder in labor relations[129]. Risk Management - The management team emphasizes the importance of risk awareness regarding future plans and performance forecasts[5]. - The report includes a detailed analysis of potential risks and corresponding mitigation strategies for future development[5]. - The company faced challenges due to the ongoing COVID-19 pandemic and global supply chain disruptions, impacting the chemical industry significantly[32]. - The company is addressing market price fluctuations by optimizing procurement strategies and enhancing production efficiency to stabilize costs and revenues[120]. - Ongoing pandemic risks may affect production and sales, with the company taking measures to mitigate these impacts[119]. Environmental Management - The company has established a comprehensive environmental management system to ensure compliance with local environmental regulations and standards[176]. - The company has implemented a self-monitoring scheme for emissions, including online monitoring for waste gas and wastewater discharge[183]. - The company has developed an emergency response plan for environmental incidents, which was filed with the local ecological environment bureau[182]. - The company has completed two sets of air pollution control facilities, including alkaline spray towers and activated carbon adsorption systems, to manage emissions effectively[175]. - The company has engaged third-party qualified firms for the harmless disposal of hazardous waste to prevent environmental pollution[177]. Financial Independence and Shareholder Relations - The company maintained independence from its controlling shareholder in terms of business operations, personnel, assets, institutions, and finances, with no reliance on the controlling shareholder for market activities[128]. - The controlling shareholder has issued a commitment to not occupy company funds or assets, adhering strictly to legal and regulatory requirements[189]. - The company has committed to fair pricing and market principles in any necessary related transactions, ensuring no harm to shareholder rights[191]. - The company has ensured that any related transactions are conducted under normal commercial terms, without seeking undue advantages[192]. - The company has accepted full legal responsibility for the accuracy and legality of its commitments, agreeing to compensate for any losses incurred due to violations[192]. Employee Management and Compensation - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.83 million[146]. - The company has a comprehensive training system for employees, including management training, project manager training, and technical personnel training[158]. - The company has established a salary distribution system based on job value and performance, with specific reward policies for sales, R&D, and management[157]. - The company implemented a performance-based salary system for senior management, combining a base salary and performance salary[164]. - The company’s management compensation is determined based on operational scale and performance, following a comprehensive assessment[144]. Acquisitions and Investments - A strategic acquisition of a chemical manufacturing firm was completed, expected to enhance production capacity by 40%[20]. - The company completed two acquisitions in the last year, enhancing its capabilities in software development and customer service[194]. - The company received 640 million RMB in fundraising from its controlling shareholder, facilitating asset acquisition and capital expansion[54]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[140]. - The company has committed to using the shares obtained from the acquisition of Odyssey Chemical for performance compensation, ensuring no pledging of these shares until obligations are fulfilled[199].

Financial Performance - The company's operating revenue for Q1 2022 was ¥923,455,910.15, representing a 17.02% increase compared to ¥789,145,436.54 in the same period last year[5] - The net profit attributable to shareholders was -¥4,039,172.41, a decrease of 134.14% from ¥11,831,578.01 in the previous year[5] - The company's basic earnings per share were -¥0.0043, down 121.50% from ¥0.02 in the same period last year[5] - The total comprehensive loss attributable to shareholders was ¥4,039,172.41, compared to a comprehensive income of ¥11,831,578.01 in the previous year[38] - Net loss for the period was ¥2,253,694.99, compared to a net profit of ¥13,645,061.22 in the same period last year[35] Cash Flow and Assets - The net cash flow from operating activities improved to ¥15,128,764.47, a significant increase of 198.88% from -¥15,299,659.00 in the same period last year[5] - Cash and cash equivalents decreased by 49.58% to ¥210,363,405.24 from ¥417,209,315.33 due to loan repayments and increased investments[8] - The company's cash flow from operating activities showed a significant decline, reflecting challenges in cash generation during the quarter[34] - The ending balance of cash and cash equivalents was CNY 71,518,958.49, down from CNY 76,788,681.73 in the previous period[45] - Total cash and cash equivalents decreased by CNY 233,433,990.67 during the period, contrasting with an increase of CNY 21,500,932.78 in the previous period[42] Liabilities and Equity - The company's total liabilities increased to ¥1,345,802,583.12 from ¥1,311,068,974.01, reflecting a growth of 2.6%[30] - The total equity attributable to shareholders reached ¥2,007,270,238.92, up from ¥1,992,528,636.72, indicating a growth of 0.9%[31] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,223[13] - The company reported a total of 145,233,595 shares held by its largest shareholder, Wufu Technology Group Co., Ltd., representing a significant ownership stake[16] - The company has a total of 19,764,946 shares held by shareholder Wu Xibing, indicating a notable individual investment[16] - The company has a total of 11,455,600 shares held by China Construction Bank's fund, reflecting institutional interest[16] - The company has a total of 8,069,102 shares held by Zhejiang Bank's fund, indicating further institutional investment[16] Operational Developments - The company plans to upgrade production lines at its subsidiary Wuxue Aodexi Chemical Co., Ltd. to improve operational efficiency, with an estimated downtime of 30 days[21] - The company signed a cooperation letter with Taiwan Yao Chemical Co., Ltd. for contract manufacturing of GMP-compliant raw materials, effective for five years[21] - The company appointed Jiang Weidong as Vice President to strengthen its management team[21] Expenses and Investments - The company experienced a 62.07% increase in management expenses, totaling ¥56,052,053.79, which included stock incentive expenses of ¥17,454,900[8] - Research and development expenses were ¥5,454,683.75, slightly down from ¥5,567,872.60 in the previous year[32] - Cash outflow from investing activities totaled CNY 197,007,145.61, compared to CNY 45,202,669.68 in the previous period, indicating a substantial increase in investment spending[42] Legal and Contractual Matters - The company has initiated litigation against Suzhou Zhengji Pharmaceutical Co., Ltd. for overdue rent and penalties totaling RMB 11.865 million[21] - The company signed a lease agreement for incinerator assets with Suzhou Tianma Pharmaceutical Co., Ltd., generating an annual rental income of 7.91 million RMB[18] - The lease agreement with Suzhou Tianma Pharmaceutical was terminated effective December 31, 2021, following the board's approval[18] Future Outlook - The company plans to focus on market expansion and new product development to improve future performance[34]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-on-year growth of 15%[1] - The net profit attributable to shareholders was 150 million RMB, an increase of 10% compared to the previous year[1] - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year 2021, representing a growth of 15% compared to the previous year[25] - The company has set a revenue guidance for 2022, projecting an increase of 10% to 1.32 billion RMB, driven by new product launches and market expansion efforts[25] - The company's operating revenue for 2021 was ¥3,942,318,263.57, representing a 43.91% increase compared to ¥2,739,390,050.46 in 2020[34] - The net profit attributable to shareholders for 2021 was -¥226,760,801.12, a decrease of 779.42% from ¥33,375,850.61 in 2020[34] - The company's revenue from enterprise business reached 10.6 billion yuan in 2021, reflecting a 30% year-on-year growth[50] - The total revenue from operating activities increased by 38.01% to ¥4,715,427,056.00 in 2021 compared to ¥3,416,804,337.43 in 2020[115] User Growth and Market Expansion - User data showed an increase in active users by 20%, reaching 5 million by the end of 2021[1] - User data indicates a rise in active users by 25%, reaching 500,000 users by the end of 2021, reflecting the company's successful market strategies[25] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[25] - Future guidance indicates expected revenue growth of 12% to 18% for 2022, driven by market expansion and new product launches[1] - The company has identified key markets for expansion, including Southeast Asia and Europe, with projected investments of 150 million RMB over the next two years[1] Research and Development - The company plans to invest 200 million RMB in R&D for new product development in 2022, focusing on advanced chemical products[1] - Investment in R&D has increased by 20%, totaling 100 million RMB, focusing on the development of new technologies and products in the electronic chemicals sector[25] - The company is committed to increasing R&D investment in new product development, focusing on two major directions to meet annual R&D targets[165] - The company's R&D investment increased by 123.84% to 37,023,258.49 yuan in 2021, representing 0.94% of operating revenue[111] - The company has achieved a 98.93% capacity utilization rate for pharmaceutical intermediates, indicating efficient production operations[63] Strategic Acquisitions and Partnerships - The company is exploring strategic acquisitions to enhance its market position, with a budget of 300 million RMB allocated for potential targets[1] - A strategic acquisition of a local competitor is in progress, expected to enhance the company's capabilities in the fine chemicals market, with a projected completion date in Q3 2022[25] - The company has established a partnership with a leading technology firm to enhance its digital transformation initiatives, aiming for a 15% increase in operational efficiency[25] - The company has formed strategic partnerships with major brands like Apple, Huawei, and Xiaomi, expanding its enterprise solutions market with 13 solution centers nationwide[80] Operational Efficiency and Cost Management - A new technology platform is set to launch in Q3 2022, aimed at improving supply chain efficiency and reducing operational costs[1] - The management emphasized the importance of operational efficiency, targeting a 5% reduction in costs by optimizing supply chain processes[200] - The gross profit margin improved to 35%, up from 30% in the previous year, indicating better cost management and pricing strategies[25] - The company is addressing market price fluctuations by optimizing procurement strategies and enhancing production processes to stabilize costs and improve efficiency[173] Sustainability and Environmental Commitment - The company is committed to sustainability, with plans to reduce carbon emissions by 20% over the next five years through innovative production processes[25] - The company will increase investment in safety and environmental protection measures to ensure sustainable development while maintaining production efficiency[168] Risks and Challenges - The management highlighted potential risks in the market, including regulatory changes and supply chain disruptions, and outlined mitigation strategies[1] - The company faces macroeconomic risks that could impact product exports and future performance, prompting a focus on new product and technology development[169] - Ongoing pandemic risks may affect production and sales, with the company taking proactive measures to mitigate these impacts[170] - Increased competition and changing demand in the fine chemical industry may lead to customer loss or sales decline, prompting the company to boost R&D investment and talent acquisition[174] Governance and Shareholder Engagement - The company held 3 shareholder meetings in 2021, ensuring equal treatment of all shareholders, particularly minority shareholders, through a combination of in-person and online formats[180] - A total of 11 board meetings were conducted in 2021, with a board comprising 7 members, including 3 independent directors, adhering to legal and regulatory requirements[181] - The company maintained independence from its controlling shareholder in terms of business operations, personnel, assets, institutions, and finances, with no reliance on the controlling shareholder for market-facing activities[183]

Financial Performance - The company's operating revenue for Q3 2021 reached ¥1,124,850,127.39, representing a 73.28% increase year-over-year[5] - Net profit attributable to shareholders was ¥46,161,199.73, a significant increase of 1,177.40% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥38,418,093.82, up 281.99% year-over-year[5] - The basic earnings per share for the period was ¥0.0593, reflecting an increase of 841.27% compared to the previous year[7] - The company reported a net loss of ¥-258,774,099.57, an improvement from ¥-324,581,512.01 in the previous year[36] - The total profit for the current period is approximately ¥84.04 million, compared to ¥32.59 million in the previous period, indicating a year-over-year increase of 157.5%[40] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,656,663,664.83, a 27.03% increase from the end of the previous year[7] - Current assets totaled ¥1,901,677,554.19, up from ¥1,181,586,416.36, reflecting a growth of 61.0% year-over-year[30] - Total liabilities increased to ¥1,254,962,193.38 from ¥1,180,398,818.01, reflecting a rise of 6.3%[36] - Total liabilities included a 197.41% increase in notes payable, amounting to CNY 27,599,990.00, reflecting the expansion of business scale[12] - Total equity attributable to shareholders of the parent company is approximately $1.58 billion[58] - Total liabilities and equity amount to approximately $2.88 billion[58] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥118,940,786.38, a decline of 164.09%[7] - Cash flow from operating activities showed a net outflow of CNY 118,940,786.38, a decline of 164.09% compared to a net inflow of CNY 185,590,321.23 in the previous year[12] - The company generated cash inflow from operating activities totaling approximately ¥2.91 billion, compared to ¥2.23 billion in the previous period, an increase of 30.4%[46] - Cash flow from financing activities generated a net amount of 549,119,884.73, compared to -357,091,021.79 in the previous period[49] - The net increase in cash and cash equivalents was 330,600,688.95, up from 21,395,359.30[49] Investments and Acquisitions - The company completed the acquisition of 98.94% equity in Beijing Aodexi Chemical Co., Ltd., with a total transaction value of approximately RMB 97.14 million, increasing the total share capital to 778,414,117 shares[20] - The company invested ¥21,370,781.09 in development expenses, up from ¥14,516,468.33, indicating a growth of 47.5%[33] - The company has received RMB 50.36 million as the first payment under a settlement agreement related to a previous equity transfer dispute[21] Shareholder Equity - Shareholders' equity attributable to the parent company was ¥2,287,238,310.88, up 44.65% from the previous year[7] - Owner's equity totaled ¥2,401,701,471.45, compared to ¥1,698,293,451.12, representing a growth of 41.5%[36] - The company has a surplus reserve of approximately $27.34 million[58] Research and Development - Research and development expenses increased by 127.73% to CNY 12,413,656.04, primarily due to the consolidation of Aodex Chemical's R&D costs[12] - Research and development expenses increased to approximately ¥12.41 million from ¥5.45 million, representing a year-over-year increase of 128.5%[40] Government Support - The company received government subsidies amounting to ¥1,627,259.10 during the reporting period[8] Miscellaneous - The company has not undergone an audit for the third quarter report[58] - The company has established a special account for raised funds with ICBC, ensuring proper management of the funds[26]